natgillin/translations-raw huggingface dataset:
The recommended dose, including for patients with a condition called ‘atrial fibrillation' (an irregular heartbeat), is one 75 mg tablet of Clopidogrel Krka per day to be taken orally with or without food, and at the same time each day.
Preporučena doza, uključujući za bolesnike sa stanjem zvanim "fibrilacija atrija" (nepravilni otkucaji srca), je jedna tableta lijeka Clopidogrel Krka od 75 mg dnevno koja se uzima kroz usta s obrokom ili između obroka, u isto vrijeme svaki dan.
You have been prescribed Clopidogrel Krka to help prevent blood clots and reduce the risk of these severe events because: - You have a condition of hardening of arteries (also known as atherosclerosis), and - You have previously experienced a heart attack, stroke or have a condition known as peripheral arterial disease, or - You have experienced a severe type of chest pain known as ‘unstable angina' or ‘myocardial infarction' (heart attack).
Clopidogrel Krka Vam je propisan za sprječavanje stvaranja krvnih ugrušaka i smanjivanje opasnosti od ovih ozbiljnih događaja jer: - imate otvrdnuće arterija (koje se još zove ateroskleroza) te - ste već imali srčani udar, moždani udar ili imate stanje koje se zove bolest perifernih arterija. - ste imali teški oblik boli u prsištu, poznat pod nazivom “nestabilna angina” ili “infarkt miokarda” (srčani udar).
If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg of Clopidogrel Krka (4 tablets of 75 mg) once at the start of treatment.
Ako ste imali jake bolove u prsištu (nestabilna angina ili srčani udar), liječnik Vam u početku liječenja može jednokratno dati 300 mg lijeka Clopidogrel Krka (4 tablete od po 75 mg).
7 film-coated tablets: EU/1/09/556/001 14 film-coated tablets: EU/1/09/556/002 28 film-coated tablets: EU/1/09/556/003 30 film-coated tablets: EU/1/09/556/004 50 film-coated tablets: EU/1/09/556/005 56 film-coated tablets: EU/1/09/556/006 60 film-coated tablets: EU/1/09/556/010 84 film-coated tablets: EU/1/09/556/007 90 film-coated tablets: EU/1/09/556/008 100 film-coated tablets: EU/1/09/556/009 112 film-coated tablets: EU/1/09/556/012 120 film-coated tablets: EU/1/09/556/011
100 filmom obloženih tableta: EU/1/09/556/009 112 filmom obloženih tableta: EU/1/09/556/012 120 filmom obloženih tableta: EU/1/09/556/011
• You should tell your doctor if a surgery (including dental) is planned.
Dok uzimate Clopidogrel Krka: - Obavijestite svog liječnika ako planirate kirurški zahvat (uključujući stomatološke zahvate).
Polyvinyl alcohol Titanium dioxide (E171) Red iron oxide (E172) Yellow iron oxide (E172) Talc
Film ovojnica: poli(vinilni alkohol) titanijev dioksid (E171) željezov oksid, crveni (E172) željezov oksid, žuti (E172) talk makrogol 3000
In CURE, there was no excess in major bleeds with clopidogrel plus ASA within 7 days after coronary bypass graft surgery in patients who stopped therapy more than five days prior to surgery.
U studiji CURE s klopidogrelom uz ASK nije bilo povećanog broja velikih krvarenja tijekom 7 dana nakon ugrađivanja srčane premosnice u bolesnika koji su lijekove prestali uzimati više od pet dana prije kirurškog zahvata.
If you stop taking Clopidogrel Krka
Ako prestanete uzimati Clopidogrel Krka
Then, the recommended dose is one 75 mg tablet of Clopidogrel Krka per day as described above.
Krka je jedna tableta od 75 mg dnevno, kao što je opisano iznad.
- Adult patients suffering from acute coronary syndrome: - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
- odraslih bolesnika koji boluju od akutnog koronarnog sindroma: - Akutni koronarni sindrom bez elevacije ST-segmenta (nestabilna angina ili non-Q infarkt miokarda), uključujući bolesnike koji se podvrgavaju ugradnji stenta nakon perkutane koronarne intervencije, u kombinaciji s acetilsalicilatnom kiselinom (ASK).
- Hypersensitivity to the active substance or to any of the excipients listed in section 2 or section
- Preosjetljivost na djelatnu tvar ili neku od pomoćnih tvari navedenih u dijelu 2 ili dijelu 6.1.
New cardiovascular events (primary endpoint) were prevented, with relative risk reductions of 22% (CI: 8.6, 33.4), 32% (CI: 12.8, 46.4), 4% (CI: -26.9, 26.7), 6% (CI: -33.5, 34.3) and 14% (CI: -31.6, 44.2), during the 0-1, 1-3, 3-6, 6-9 and 9-12 month study intervals, respectively.
Novi su kardiovaskularni događaji (primarni ishod) spriječeni, sa smanjenjem relativnoga rizika od 22% (CI: 8,6, 33,4), 32% (CI: 12,8, 46,4), 4% (CI: -26,9, 26,7), 6%
You should specifically tell your doctor if you take - medicines that may increase your risk of bleeding such as: o oral anticoagulants, medicines used to reduce blood clotting, o a non-steroidal anti-inflammatory medicine, usually used to treat painful and/or inflammatory conditions of muscle or joints, o heparin or any other injectable medicine used to reduce blood clotting, o ticlopidine, other antiplatelet agent, o a selective serotonin reuptake inhibitor (including but not restricted to fluoxetine or fluvoxamine), medicines usually used to treat depression, - omeprazole or esomeprazole, medicines to treat upset stomach, - fluconazole or voriconazole, medicines to treat fungal infections, - efavirenz, a medicine to treat HIV (human immunodeficiency virus) infections,
Posebno je važno obavijestiti liječnika ako uzimate - lijekove koji mogu povećati rizik od krvarenja, na primjer: - oralne antikoagulanse, lijekove koji smanjuju zgrušavanje krvi, - nesteroidne protuupalne lijekove, koji se obično primjenjuju za liječenje bolnih i/ili upalnih stanja mišića ili zglobova, - heparin ili bilo koji drugi lijek koji se daje putem injekcije za smanjivanje zgrušavanja krvi, - tiklopidin, drugi antitrombocitni lijek, - selektivne inhibitore ponovne pohrane serotonina (uključujući, ali ne ograničeno na fluoksetin ili fluvoksamin), lijekove koji se obično koriste za liječenje depresije, - omeprazol ili esomeprazol, lijekove za smanjenje želučanih tegoba, - flukonazol ili vorikonazol, lijekove koji se primjenjuju za liječenje gljivičnih infekcija, - efavirenz, lijek koji se primjenjuje za liječenje HIV (virus humane imunodeficijencije) infekcija, - karbamazepin, lijek koji se primjenjuje za liječenje nekih oblika epilepsije, - moklobemid, lijek za liječenje depresije, - repaglinid, lijek za liječenje dijabetesa, - paklitaksel, lijek za liječenje raka,
In patients suffering from acute coronary syndrome: - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), clopidogrel treatment should be initiated with a single 300 mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily).
Akutni koronarni sindrom bez elevacije ST-segmenta (nestabilna angina ili non-Q infarkt miokarda): liječenje klopidogrelom treba započeti s jednokratnom udarnom dozom od 300 mg, a zatim nastaviti sa 75 mg jedanput dnevno (uz acetilsalicilatnu kiselinu (ASK) 75 mg do 325 mg dnevno).
The CAPRIE study included 19,185 patients with atherothrombosis as manifested by recent myocardial infarction (<35 days), recent ischaemic stroke (between 7 days and 6 months) or established peripheral arterial disease (PAD).
Nedavni infarkt miokarda (IM), nedavni moždani udar ili utvrđena bolest perifernih arterija Studija CAPRIE uključivala je 19 185 bolesnika s aterotrombozom koja se manifestirala kao nedavni infarkt miokarda (<35 dana), nedavni ishemijski moždani udar (između 7 dana i 6 mjeseci) ili utvrđena bolest perifernih arterija (BPA).
If you forget to take Clopidogrel Krka
Ako ste zaboravili uzeti Clopidogrel Krka
Clopidogrel Krka is taken by adults to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death).
Krka uzimaju odrasli za sprječavanje stvaranja krvnih ugrušaka (tromba) u otvrdnutim krvnim žilama (arterijama), a taj poremećaj zove se aterotromboza i može dovesti do aterotrombotičkih događaja (kao što su moždani udar, srčani udar ili smrt).
- ST segment elevation acute myocardial infarction: clopidogrel should be given as a single daily dose of 75 mg initiated with a 300 mg loading dose in combination with ASA and with or without thrombolytics.
Akutni infarkt miokarda s elevacijom ST-segmenta: liječenje klopidogrelom provodi se jednom dnevnom dozom od 75 mg, a započinje udarnom dozom od 300 mg u kombinaciji s ASK te sa ili bez trombolitika.
How to take Clopidogrel Krka
Kako uzimati Clopidogrel Krka
OTHER
II
If you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking Clopidogrel Krka.
Ako se bilo što od navedenog odnosi na Vas, ili niste sigurni, obratite se svom liječniku prije uzimanja Clopidogrela Krka.
Clopidogrel Krka 75 mg film-coated tablets
Clopidogrel Krka 75 mg filmom obložene tablete
Clopidogrel Krka 75 mg film-coated tablets clopidogrel
Clopidogrel Krka 75 mg filmom obložene tablete klopidogrel
Clopidogrel is indicated in: - Adult patients suffering from myocardial infarction (from a few days until less than 35 days),
Sekundarna prevencija aterotrombotičkih događaja Klopidogrel je indiciran u: - odraslih bolesnika koji su pretrpjeli infarkt miokarda (u rasponu od nekoliko do najviše
There was no evidence of carcinogenic effect when clopidogrel was administered for 78 weeks to mice and 104 weeks to rats when given at doses up to
Nije bilo dokaza o kancerogenim učincima kad se klopidogrel davao miševima 78 tjedana i štakorima 104 tjedna u dozama do 77 mg/kg dnevno (što predstavlja barem 25 puta veću izloženost nego u ljudi koji primaju kliničku dozu od 75 mg/dan).
How to store Clopidogrel Krka
Kako čuvati Clopidogrel Krka
Driving and using machines Clopidogrel Krka is unlikely to affect your ability to drive or to use machines.
Krka ne bi trebao utjecati na Vašu sposobnost upravljanja vozilima ili strojevima.
Clopidogrel Krka with food and drink Clopidogrel Krka may be taken with or without food.
Krka se može uzimati s obrokom ili bez obroka.
- Severe hepatic impairment.
- Teško oštećenje funkcije jetre.
At steady state, the average inhibition level observed with a dose of 75 mg per day was between 40% and 60%.
75 mg dnevno, iznosi između 40% i 60%.
In patients with atrial fibrillation, clopidogrel should be given as a single daily dose of 75 mg. ASA (75-100 mg daily) should be initiated and continued in combination with clopidogrel (see section
ASK (75100 mg dnevno) treba istovremeno započeti i nastaviti davati u kombinaciji s klopidogrelom (vidjeti dio 5.1).
In CLARITY, there was an overall increase in bleeding in the clopidogrel plus ASA group vs. the placebo plus ASA group.The incidence of major bleeding was similar between groups.
U studiji CLARITY, uočeno je ukupno povećanje krvarenja u grupi klopidogrel uz ASK u odnosu na skupinu koja je uzimala placebo uz ASK.
• if you have a risk of bleeding such as - a medical condition that puts you at risk of internal bleeding (such as a stomach ulcer) - a blood disorder that makes you prone to internal bleeding (bleeding inside any tissues, organs or joints of your body).
Nemojte uzimati Clopidogrel Krka - ako ste alergični na klopidogrel ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.). - ako imate poremećaj koji izaziva krvarenje, kao što je, primjerice, želučani čir ili krvarenje u mozgu.
Skin and subcutaneous tissue disorders
Krka i acetilsalicilatne kiseline.
What you need to know before you take Clopidogrel Krka 3.
Što je Clopidogrel Krka i za što se koristi Što morate znati prije nego počnete uzmati Clopidogrel Krka Kako uzimati Clopidogrel Krka Moguće nuspojave
Both active substances have been available in the European Union (EU) for a number of years.
Obje djelatne tvari dostupne su u Europskoj uniji (EU) već više godina.
This summary was last updated in 09-2014.
Sažetak je posljednji put ažuriran: 09-2014.
Acetylsalicylic acid has been available for over 100 years.
Acetilsalicilna kiselina dostupna je preko 100 godina.
It can be used in the following groups of patients who have a condition known as ‘acute coronary syndrome':
Može se koristiti u sljedećim skupinama bolesnika koji pate od stanja zvanog „akutni koronarni sindrom”:
The Committee also considered that combining both active substances in a single tablet simplifies treatment for patients as they will need to take fewer tablets.
Povjerenstvo je također smatralo da kombinacija obje djelatne tvari u jednoj tableti pojednostavljuje liječenje za bolesnike jer moraju uzimati manje tableta.
Clopidogrel has been authorised since 1998 for reducing platelet aggregation, and is often used in combination with acetylsalicylic acid.
Klopidogrel je odobren od 1998. godine za redukciju agregacije trombocita i često se koristi u kombinaciji s acetilasalicilnom kiselinom.
Clopidogrel/Acetylsalicylic acid Teva must not be used during the last three months of pregnancy.
Klopidogrel/acetilsalicilna kiselina Teva ne smije se koristiti tijekom posljednja tri mjeseca trudnoće.
The full EPAR and risk management plan summary for Clopidogrel/Acetylsalicylic acid Teva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Cjeloviti EPAR kao i sažetak plana upravljanja rizikom za lijek nalaze se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
• patients being treated for heart attack with ST-segment elevation, when the doctor thinks that they would benefit from treatment to dissolve blood clots.
• bolesnici liječeni od srčanog udara s povišenjem ST segmenta kada liječnik smatra da će imati koristi od terapije za rastvaranje krvnih ugrušaka.
The European Commission granted a marketing authorisation valid throughout the European Union for Clopidogrel/Acetylsalicylic acid Teva on 01 September 2014.
Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Klopidogrel/acetilsalicilna kiselina Teva na snazi u Europskoj uniji od 01 rujna 2014.
The CHMP noted that both active substances in Clopidogrel/Acetylsalicylic acid Teva have been used for several years to reduce the risk of heart attack and when taken together they can reduce the risk more than each component can alone.
CHMP je uočio da su obje djelatne tvari u lijeku Klopidogrel/acetilsalicilna kiselina Teva korištene tijekom nekoliko godina kako bi se smanjio rizik od srčanog udara i da kad se uzimaju zajedno mogu smanjiti rizik više nego kad se uzimaju zasebno.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Clopidogrel/Acetylsalicylic acid Teva's benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji odlučio je da koristi od lijeka Klopidogrel/acetilsalicilna kiselina Teva nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za korištenje u Europskoj uniji.
This stops the platelets becoming ‘sticky', reducing the risk of a blood clot forming.
To sprječava da trombociti postanu ‚ljepljivi', smanjuje rizik od nastanka krvnog ugruška.
The combination of the two active substances has an additive effect, reducing the risk of blood clots forming more than either medicine alone.
Kombinacija ove dvije djelatne tvari imala je aditivni učinak smanjujući rizik od formiranja krvnih ugrušaka više nego svaki lijek zasebno.
The medicine is taken as a single tablet daily in place of the clopidogrel and acetylsalicylic acid tablets that the patient has already been taking separately.
Lijek se uzima kao jedna tableta dnevno umjesto pojedinačnih tableta klopidogrela i acetilsalicilne kiseline koje bolesnik već uzima.
This means that they help to prevent blood cells called platelets from sticking together and forming clots, thus helping to prevent another heart attack.
To znači da pomaže u sprječavanju od sljepljivanja krvnih stanica zvanih trombociti i formiranja ugrušaka te tako pomaže spriječiti drugi srčani udar.
Because the two active substances have been used together for a number of years, the company presented the results of studies showing that the active substances in Clopidogrel/Acetylsalicylic acid Teva are absorbed in the body in the same way when taken in a single tablet as when the two medicines are taken separately.
S obzirom da se dvije djelatne tvari koriste skupa tijekom duljeg vremena tvrtka je prikazala rezultate ispitivanja koji pokazuju da se djelatne tvari u lijeku Klopidogrel/acetilsalicilna kiselina Teva apsorbiraju u tijelu na isti način kao i kad se uzmu kao pojedinačne tablete i kao u jednoj tableti.
It also presented the results of 3 previous studies involving in total over 61,000 patients with unstable angina or who had had a heart attack, which showed that the combination of clopidogrel and acetylsalicylic acid taken as separate tablets was more effective at preventing events such as heart attacks than acetylsalicylic acid alone.
Također prikazuje rezultate tri prethodna ispitivanja koja su ukupno uključivala 61 000 bolesnika s nestabilnom anginom ili koji su imali srčani udar što je pokazalo da je kombinacija klopidogrela i acetilsalicilne kiseline koji se uzimaju kao zasebne tablete bila djelotvornija.
Acetylsalicylic acid stops the platelets sticking together by blocking an enzyme called prostaglandin cyclo-oxygenase.
Acetilsalicilna kiselina zaustavlja lijepljenje trombocita blokadom enzima zvanog prostaglandin ciklooksigenaza.
Clopidogrel stops the platelets sticking together by blocking a substance called ADP from attaching to a special receptor on their surface.
Klopidogrel zaustavlja sljepljivanje trombocita sprječavajući da se tvar ADP pričvrsti na poseban receptor na njihovoj površini.
This is a summary of the European public assessment report (EPAR) for Clopidogrel/Acetylsalicylic acid Teva.
Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Klopidogrel/acetilsalicilna kiselina Teva.
Clopidogrel/Acetylsalicylic acid Teva is available as tablets containing 75 mg clopidogrel, either with 75 mg or 100 mg acetylsalicylic acid.
Lijek Klopidogrel/acetilsalicilna kiselina Teva dostupan je u obliku tableta koje sadrže 75 mg klopidogrela bilo sa 75 ili 100 mg acetilsalicilne kiseline.
Clopidogrel/Acetylsalicylic acid Teva must not be used in people who are hypersensitive (allergic) to clopidogrel, non-steroidal anti-inflammatory drugs (NSAIDs, used to relieve pain and inflammation) such as acetylsalicylic acid, or any of the other ingredients in Clopidogrel/Acetylsalicylic acid Teva.
Klopidogrel/acetilsalicilna kiselina Teva ne smije se koristiti u osoba koje su preosjetljive (alergične) na klopidogrel, nesteroidne protuupalne lijekove (NSAIDs, koji se koriste za olakšavanje boli i upale) poput acetilsalicilne kiseline ili bilo kojeg drugog sastojka u lijeku Klopidogrel/acetilsalicilna kiselina Teva.
It must not be used in patients who have a disease that is causing bleeding, such as stomach ulcer or bleeding in the brain, or in patients with mastocytosis (high blood levels of certain white blood cells called mast cells).
Ne smije se koristiti u bolesnika koji imaju bolest koja uzrokuje krvarenje poput vrijeda na želudcu ili krvarenja u mozak ili u bolesnika s mastocitozom (visokim razinama određenih vrsta leukocita u krvi, zvanom mast stanice).
It is used to prevent problems caused by blood clots, such as a heart attack, in adults who are already taking both clopidogrel and acetylsalicylic acid (known commonly as aspirin) as separate tablets.
Koristi se za sprječavanje problema uzrokovanih krvnim ugruškom poput srčanog udara u odraslih osoba koje uzimaju i klopidogrel i acetilsalicilnu kiselinu (poznatiju kao aspirin) u zasebnim tabletama.
The most common side effects with Clopidogrel/Acetylsalicylic acid Teva (which may affect up to 1 in 10 people) are haematoma (a collection of blood under the skin), epistaxis (nosebleeds), gastrointestinal haemorrhage (bleeding in the stomach or gut), diarrhoea, abdominal pain (stomach ache), dyspepsia (heartburn), bruising, and bleeding where the skin is punctured.
Najčešće nuspojave lijeka Klopidogrel/acetilsalicilna kiselina Teva (kod više od 1 na 10 osoba) su hematom (nakupljanje krvi pod kožom), epistaksa (krvarenje u nos), krvarenje u probavnom sustavu (krvarenje u želudcu ili crijevima), proljev, bol u trbuhu, dispepsija (žgaravica), nastanak modrica i krvarenje na mjestu punkcije kože.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Clopidogrel/Acetylsalicylic acid Teva, including the appropriate precautions to be followed by healthcare professionals and patients.
Na temelju tog plana, u sažetku opisa svojstava lijeka kao i u uputi o lijeku za lijek Klopidogrel/acetilsalicilna kiselina Teva nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
It must not be used in patients who have severely reduced liver or kidney function, or who have a medical condition that includes a combination of asthma, rhinitis (stuffy and runny nose) and nasal polyps (growths in the lining of the nose).
Ne smije se koristiti u bolesnika koji imaju jako oštećenu funkciju jetre ili bubrega ili koji imaju medicinsko stanje koje uključuje kombinaciju astme, rinitisa (začepljenog i curećeg nosa) i polipe na nosu (izrasline na sluznici nosa).
This reduces the production of a substance called thromboxane, which normally helps clots to form by binding platelets together.
To smanjuje nastanak tvari zvane tromboksan koja inače pomaže da se formiraju ugrušci lijepljenjem trombocita.
What measures are being taken to ensure the safe and effective use of Clopidogrel/Acetylsalicylic acid Teva?
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Klopidogrel/acetilsalicilna kiselina Teva?
Clopidogrel/Acetylsalicylic acid Teva clopidogrel / acetylsalicylic acid
Klopidogrel/acetilsalicilna kiselina Teva klopidogrel/acetilsalicilna kiselina
Both active substances in Clopidogrel/Acetylsalicylic acid Teva, clopidogrel and acetylsalicylic acid, are antiplatelet medicines.
Obje djelatne tvari u lijeku Klopidogrel/acetilsalicilna kiselina Teva, klopidogrel i acetilsalicilna kiselina lijekovi su protiv agregacije trombocita.
For more information about treatment with Clopidogrel/Acetylsalicylic acid Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Više informacija o terapiji lijekom pročitajte u uputi o lijeku (također dio EPAR-a), ili se obratite svom liječniku ili ljekarniku.
Clopidogrel/Acetylsalicylic acid Teva is a blood thinning medicine that contains two active substances, clopidogrel and acetylsalicylic acid.
Klopidogrel/acetilsalicilna kiselina Teva lijek je za razrjeđivanje krvi koji sadrži dvije djelatne tvari, klopidogrel i acetilsalicilnu kiselinu.
A risk management plan has been developed to ensure that Clopidogrel/Acetylsalicylic acid Teva is used as safely as possible.
Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Klopidogrel/acetilsalicilna kiselina Teva.
What are the risks associated with Clopidogrel/Acetylsalicylic acid Teva?
Koji su rizici povezani s lijekom Klopidogrel/acetilsalicilna kiselina Teva?
Other information about Clopidogrel/Acetylsalicylic acid Teva
Ostale informacije o lijeku Klopidogrel/acetilsalicilna kiselina Teva
What is Clopidogrel/Acetylsalicylic acid Teva and what is it used for?
Što je Klopidogrel/acetilsalicilna kiselina Teva i za što se koristi?
• patients who have unstable angina (a severe type of chest pain) or have had a heart attack with no ‘ST-segment elevation' (an abnormal reading on the ECG or electrocardiogram), including those who are having a stent (a short tube) inserted into an artery to prevent it from closing up;
‚povišenja ST segmenta' (nenormalno očitavanje EKG-a ili elektrokardiograma), uključujući i one koji imaju stent (kratku cjevčicu) umetnut u arteriju radi sprječavanja njenog zatvaranja;